New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies Novartis, 21 Mar 2013 Accessed on 25 Mar 2013 from http://www.novartis.com/newsroom/media-releases/en/2013/1686799.shtml. CommentRecommendBookmarkWatch